Menu Search
Equities

Wakamoto Pharmaceutical Co Ltd

4512:TYO

Wakamoto Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)237.00
  • Today's Change1.00 / 0.42%
  • Shares traded101.40k
  • 1 Year change+19.10%
  • Beta0.9844
Data delayed at least 20 minutes, as of Nov 08 2024 06:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in JPYIncome statement in JPYView more

Year on year Wakamoto Pharmaceutical Co Ltd's revenues fell -10.65% from 8.66bn to 7.74bn. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from 138.26m to 108.96m, a -21.19% decrease.
Gross margin47.52%
Net profit margin2.40%
Operating margin-2.12%
Return on assets1.22%
Return on equity1.58%
Return on investment1.39%
More ▼

Cash flow in JPYView more

In 2024, cash reserves at Wakamoto Pharmaceutical Co Ltd fell by 214.68m. Cash Flow from Investing was negative at 2.35m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 107.34m for operations while cash used for financing totalled 104.99m.
Cash flow per share17.53
Price/Cash flow per share13.57
Book value per share344.22
Tangible book value per share335.17
More ▼

Balance sheet in JPYView more

Wakamoto Pharmaceutical Co Ltd appears to have little financial risk as the company holds a substantial amount of cash on its books with little or no debt.
Current ratio4.69
Quick ratio3.48
Total debt/total equity0.0084
Total debt/total capital0.0083
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.